Effect of Favipiravir on outpatient treatment of Covid-19

Phase 3

Recruiting

• Conditions: Covid-19.; U07COVID-19, virus identified; U07.1

• Registration Number: IRCT20171219037964N3
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

definite case of Covid-19
age over 18
presented within 5 days from the start of sign and symptoms

Exclusion Criteria

severe cases with SpO2 under 90
using an antiviral in previous two weeks
previous infection with covid-19
using an steroid in previous two weeks
being under treatment with steroid
previous allergic to Favipiravir
renal failure
hepatic failure
pregnancy
lactating

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment failure. Timepoint: days 3, 7, 14, 21, 28 from the start of treatment. Method of measurement: interview with patients.;Side effects. Timepoint: days 3 and 7 after the start of treatment. Method of measurement: interview with patients.